Trial · NCT03605680
Participant flow28
How many started, completed or left each group, period by period.
1 to 20 of 28
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| SB Placebo Run-in Period (1 Week) | STARTED | Single-blind (SB) Run-in Period: Placebo | 604 | |
| SB Placebo Run-in Period (1 Week) | STARTED | Double-blind Treatment Period: Centanafadine SR 200 mg | 0 | |
| SB Placebo Run-in Period (1 Week) | STARTED | Double-blind Treatment Period: Centanafadine SR 400 mg | 0 | |
| SB Placebo Run-in Period (1 Week) | STARTED | Double-blind Treatment Period: Placebo | 0 | |
| SB Placebo Run-in Period (1 Week) | Treated | Single-blind (SB) Run-in Period: Placebo | 584 | |
| SB Placebo Run-in Period (1 Week) | Treated | Double-blind Treatment Period: Centanafadine SR 200 mg | 0 | |
| SB Placebo Run-in Period (1 Week) | Treated | Double-blind Treatment Period: Centanafadine SR 400 mg | 0 | |
| SB Placebo Run-in Period (1 Week) | Treated | Double-blind Treatment Period: Placebo | 0 | |
| SB Placebo Run-in Period (1 Week) | COMPLETED | Single-blind (SB) Run-in Period: Placebo | 466 | |
| SB Placebo Run-in Period (1 Week) | COMPLETED | Double-blind Treatment Period: Centanafadine SR 200 mg | 0 | |
| SB Placebo Run-in Period (1 Week) | COMPLETED | Double-blind Treatment Period: Centanafadine SR 400 mg | 0 | |
| SB Placebo Run-in Period (1 Week) | COMPLETED | Double-blind Treatment Period: Placebo | 0 | |
| SB Placebo Run-in Period (1 Week) | NOT COMPLETED | Single-blind (SB) Run-in Period: Placebo | 138 | |
| SB Placebo Run-in Period (1 Week) | NOT COMPLETED | Double-blind Treatment Period: Centanafadine SR 200 mg | 0 | |
| SB Placebo Run-in Period (1 Week) | NOT COMPLETED | Double-blind Treatment Period: Centanafadine SR 400 mg | 0 | |
| SB Placebo Run-in Period (1 Week) | NOT COMPLETED | Double-blind Treatment Period: Placebo | 0 | |
| Double-blind Treatment Period (6 Weeks) | STARTED | Single-blind (SB) Run-in Period: Placebo | 0 | |
| Double-blind Treatment Period (6 Weeks) | STARTED | Double-blind Treatment Period: Centanafadine SR 200 mg | 154 | |
| Double-blind Treatment Period (6 Weeks) | STARTED | Double-blind Treatment Period: Centanafadine SR 400 mg | 156 | |
| Double-blind Treatment Period (6 Weeks) | STARTED | Double-blind Treatment Period: Placebo | 156 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03605680/flow